Why biosimilars matter: insights from a health care leader
In this special sponsored episode, we focus on biosimilar medications and how they can benefit patients. I'm joined by Tim de Gavre, the VP and chief commercial officer at Sandoz, a member of the Sandoz U.S. Executive Committee, and a graduate of The...
In this special sponsored episode, we focus on biosimilar medications and how they can benefit patients. I'm joined by Tim de Gavre, the VP and chief commercial officer at Sandoz, a member of the Sandoz U.S. Executive Committee, and a graduate of The Wharton School and Princeton University.
In this episode, we'll dive into the world of biosimilars and explore what they are, how they differ from generic medications, and the various conditions they can treat. We'll also discuss the benefits of biosimilars for both health care providers and patients, as well as the current state of the biosimilar market in the U.S. and internationally. We'll examine the impact of biosimilars on health care costs and the readiness of the U.S. health care system for greater adoption. Finally, we'll discuss strategies for breaking down barriers to biosimilar adoption and consider the future of the U.S. biosimilar landscape.
Note: This interview was recorded in December 2022.
VISIT SPONSOR → https://Sandoz.com
SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast
RATE AND REVIEW → https://www.kevinmd.com/rate
FOLLOW ON INSTAGRAM → https://www.instagram.com/kevinphomd
FOLLOW ON TIKTOK → https://www.tiktok.com/@kevinphomd
Listen On
